.avif)
Case studies
Proven impact across the healthcare innovation journey
Explore selected examples of how Newmarket Strategy helps healthcare, life sciences and organisations move through complex market challenges.
.jpg)
From NICE Submission to NHS Patient Access: End-to-End Market Access and Government Affairs Support for a First-in-Class Brain Cancer Treatment
A global pharmaceutical company retained Newmarket Strategy across a 27-month programme to secure NHS access for a first-in-class therapeutic for a rare brain cancer affecting predominantly young adults, with no new treatment options for over 20 years. Our integrated Market Access and Government Affairs support spanned pre-NICE submission through to post-recommendation, culminating in a positive NICE technology appraisal recommendation at a commercially viable price, securing access to a life-changing treatment for patients.
mRNA cancer vaccine commercial strategy -- global biotechnology company
Newmarket Strategy provided strategic advisory support to a global biotechnology company on commercial deal structuring and stakeholder engagement for a novel oncology immunotherapy platform in the UK, centred on an established partnership with government.
NICE resubmission feasibility assessment for a rare haematological oncology asset - European specialty pharma
Newmarket Strategy supported a European specialty pharmaceutical company in assessing the feasibility of a NICE resubmission for a targeted therapy in a rare, haematological malignancy, following a material shift in the treatment landscape since termination of the original appraisal.
Challenging the investment case for a market-leading healthcare advisory business
A strategic buyer considering the acquisition of a specialist healthcare advisory business needed an independent assessment of the target’s growth prospects and the rate of return on investment. Newmarket Strategy built a bottom-up view of the market, tested the target’s revenue assumptions and competitive position, and concluded that achievable revenues were materially below those assumed in the investment case and would not support the returns being targeted.
Developing a practical, real-world guide for NHS commissioners to help drive uptake of a new medicine.
We supported a global pharmaceutical company to bridge the gap between medicine approval and real-world NHS adoption, bringing together expert commissioners and clinicians to develop practical implementation guidance.
